The ubiquitin-like modifier (UBL) family has recently generated much interest in the scientific community, as it is implicated to play important regulatory roles via novel protein-protein modification. FAT10 (diubiquitin) belongs to this family of proteins, comprising two ubiquitin-like moieties fused in tandem, and has been implicated to be involved in the maintenance of spindle integrity during mitosis. As FAT10 may play a role in the regulation of genomic stability, we examined if there is an association between FAT10 expression and hepatocellular carcinoma (HCC) or other cancers. Northern blot analyses revealed upregulation of FAT10 expression in the tumors of 90% of HCC patients. In situ hybridization as well as immunohistochemistry utilizing anti-FAT10 antibodies localized highest FAT10 expression in the nucleus of HCC hepatocytes rather than the surrounding immune and non-HCC cells. FAT10 expression was also found to be highly upregulated in other cancers of the gastrointestinal tract and female reproductive system. In conclusion, we demonstrated upregulation of FAT10 expression in various gastrointestinal and gynecological cancers. Its overexpression is unrelated to the general increase in protein synthesis or a general immune/ inflammatory response to cancer. Rather, FAT10 may modulate tumorigenesis through its reported interaction with the MAD2 spindle-assembly checkpoint protein.
Introduction
Tumorigenesis often arises from dysregulated cell-cycle control or apoptosis. The ubiquitin and ubiquitinrelated families of proteins play instrumental roles in various cellular processes including cell-cycle regulation (Jentsch and Pyrowolakis, 2000) as well as cell death/ apoptosis (Jesenberger and Jentsch, 2002 ) through modification of target proteins.
Ubiquitin is a highly conserved 76 amino-acid polypeptide that plays an important role in the conjugation of target proteins, thereby 'tagging' these proteins for degradation via the 26S proteasome pathway (Hochstrasser, 1996a,b) . The targeting of proteins for degradation by ubiquitin occurs through a cascade of events requiring participation of three enzymes, the ubiquitin-activating enzyme (E1), the carrier protein (E2) and the ubiquitin ligase (E3). The evolutionarily conserved C-terminal glycine (Gly) residue of ubiquitin is conjugated to the lysine (Lys) residue of target proteins. Polyubiquitin chains can also be formed by the attachment of a Lys residue from the preceding ubiquitin molecule (Lys48) to the C-terminal Gly residue of the next ubiquitin molecule, thus creating proteosome targeting signals (Pickart, 1997) .
The roles of ubiquitin-like family members are only beginning to be elucidated. Two different families of ubiquitin-like proteins have been reported (Jentsch and Pyrowolakis, 2000) . The ubiquitin-domain proteins (UDPs), for example, RAD23, BAG1, Elongin B and Gdx, do not form conjugates with other proteins, although they contain embedded ubiquitin-like domains. Residues outside these domains do not bear similarities to each other or to ubiquitin. The second family of ubiquitin-like proteins is known as the ubiquitin-like modifiers (UBL), and they are related in sequence to either a monomer or dimer of ubiquitin. Several members of the UBL family, including SUMO/ Setrin and RUB1/NEDD8, function as modifiers in an analogous manner to ubiquitin. Most of the UBL family members have been reported to attach covalently to other proteins via their C-termini, which also contain the conserved Gly-Gly motifs. The conjugation pathways of the studied UBL members are similar to that of ubiquitin, although their E1, E2 and E3 proteins differ (Jentsch and Pyrowolakis, 2000) .
Several ubiquitin and ubiquitin-related proteins have been associated with cell-cycle-related processes and implicated in cancer. BRCA1, a breast and ovarian cancer-specific tumor suppressor, contains a RING domain typical of E3 and exhibits ligase activity (Ruffner et al., 2001) . Mutations within the RING domain have been found to inactivate E3 activity and predispose the patient to cancer (Ruffner et al., 2001) . The UBL protein, SUMO1, has been reported to conjugate with the PML oncogene (Boddy et al., 1996; Muller et al., 1998) and associate with the 'death domains' of Fas/APO1 and tumor necrosis factor (TNF) receptor 1 (Okura et al., 1996) , while its Saccharomyies cerevisiae analog Smt3 was found to be required for chromosome segregation during mitosis (Biggins et al., 2001) . Another UBL protein NEDD8 has been shown to be essential for cell-cycle progression in mice (Tateishi et al., 2001) . The UDP protein Elongin B was found to be associated with the von Hippel Lindau (VHL) tumor suppressor in a VHL-dependent E3 complex (Iwai et al., 1999) , while the yeast UDP protein, DSK2p, was reported to be involved in spindle pole body duplication (Biggins et al., 1996) .
FAT10 is an 18 kDa protein comprising 165 aminoacid residues. It was originally discovered through the identification of expressed genes covering the HLA-F genomic locus (Fan et al., 1996) . A potential role of FAT10 in antigen presentation was suggested by its expression in mature B cells and dendritic cells (Bates et al., 1997) , and by its ability to be generally and synergistically inducible with cytokines IFNg and TNFa, but not IFNa (Raasi et al., 1999) . FAT10 belongs to the UBL family of proteins and contains two ubiquitin-like moieties fused in tandem (Jentsch and Pyrowolakis, 2000) . It is 29% identical to ubiquitin at its N-terminus and 36% identical at the C-terminus. Like ubiquitin, it has the C-terminal Gly-Gly residues. Furthermore, there is a conserved Lys residue in each moiety of FAT10 analogous to Lys48 of ubiquitin, each of which may serve as a potential site for polyubiquitination of FAT10. Interestingly, as has been found in some other UBL members, FAT10 has been reported to have potential involvement in cell-cycle regulation. FAT10 has been shown to bind noncovalently to the human spindle assembly checkpoint protein, MAD2 (Liu et al., 1999) , a protein responsible for maintaining spindle integrity during mitosis (Shah and Cleveland, 2000) . The inhibition of MAD2 function has been associated with chromosomal instability, a characteristic of many cancers (Wang et al., 2000; Gemma et al., 2001) .
In the present study, we examined if there is an association between the FAT10 expression and hepatocellular carcinoma (HCC). We report that FAT10, a gene not previously reported to be associated with HCC or other cancers, is consistently upregulated in the tumors of approximately 90% of HCC patients screened. Further analyses reveal that the strong upregulation of FAT10 expression is not limited to HCC, but is in fact a common feature of other cancers, especially those of the gastrointestinal tract and female reproductive system. We further demonstrate that FAT10 is localized to the nucleus of HCC cells. FAT10 has been implicated in cell-cycle regulation, a key modulator of tumorigenesis (Liu et al., 1999) , and this report represents the first demonstration of the upregulation of FAT10 gene expression in gastrointestinal and gynecological tumors.
Materials and methods

Patients and tissue samples
All patient samples were obtained in accordance to the Institutional Review Board (IRB) Guidelines of the Johns Hopkins University, School of Medicine, USA and guidelines of the National Cancer Center, Singapore.
Northern blot analysis
The upregulation of FAT10 expression in HCC tumors were examined in 23 HCC patients by Northern blot analysis using 15 mg of total RNA as described previously (Hooi et al., 1997) . The FAT10 (GenBank Accession number: AF123050) cDNA was first prepared from RT-PCR of total RNA extracted from liver tissue samples using FAT10-gene-specific primers. The amplified cDNA was sequenced to confirm its identity as FAT10. cDNA probes were labeled with a-32 P dCTP (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA) using Rediprime labeling kit (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA) according to the manufacturer's instructions.
The probed blot was then exposed to Biomax MS film (Kodak Inc., Rochester, NY, USA) or Fuji imaging plate (Kanagawa, Japan) and quantitated using the FluorChem TM v2.0 (Alpha Innotech Corporation, San Leandro, CA, USA) or the phosphorimager, BAS-2500 (Fujifilm, Kanagawa, Japan).
In situ hybridization
Fresh HCC tissues and their adjacent nontumorous tissues were immediately embedded in tissue freezing medium (TissueTek OCT compound, Sakura, Japan) in a cryomold (SIM-PORT, Canada) in dry ice and stored at À701C. Sections (5 mm) of the tissues were then mounted onto poly-l-lysinecoated slides and fixed immediately in 4% paraformaldehyde-PBS for 15 min at room temperature.
The unique sequence of the FAT10 cDNA was cloned into pBluescript II KS + vector (Stratagene, La Jolla, CA, USA). Clones containing inserts in the forward and reverse orientation were selected for riboprobe generation (DIG RNA labeling kit, Roche, Basel, Switzerland) as sense and antisense probes.
In situ hybridization was then performed on the sectioned tissues with the respective probes using DAKO mRNA in situ hybridization solution (DAKO, Glostrup, Denmark) following the method of Braissant and Wahli (1998) , except that the slides were treated with RNase (Komminoth et al., 1992) and washed at higher stringency. Positive signals were visualized using NBT/BCIP substrate (Roche, Basel, Switzerland).
Generation of anti-FAT10 antibodies
The open reading frame of FAT10 was cloned downstream of the N-terminal His-tag of the Gatewayt expression vector, pEXPR17, using the Gatewayt Cloning Technology (Invitrogen, Carlsbad, CA, USA) to generate pEXPR17-FAT10, which was then transformed into BL21-SI Escherichia coli cells (Invitrogen, Carlsbad, CA, USA). Recombinant FAT10 protein expression in BL21-SI cells was induced by addition of 0.3 m NaCl for 5 h and purified using Ni-NTA resin (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Fractions containing the highest amount of HisFAT10 protein were then pooled, dialyzed in water and freeze-dried. Polyclonal antibodies against the recombinant FAT10 protein were then generated in rabbits (BioGenes GmbH, Berlin, Germany) and purified over a FAT10-Sepharose column.
Immunohistochemistry
Sections (5 mm) of frozen HCC tissue tissues were fixed in acetone for 10 min at 41C, washed briefly in water and treated with freshly prepared 3% hydrogen peroxide for 10 min to block endogenous peroxidases. The slides are then incubated with 2 mg/ml of anti-FAT10 primary antibody for 30 min. A polymer-linked anti-rabbit secondary antibody is then applied using the DAKO Envision TM AP KIT (Code K4016) (DAKO, Glostrup, Denmark) for another 30 min. Freshly prepared chromogen solution (fast red) is then applied and the slides are counterstained with Harris Haematoxylin (Gill's II Haematoxylin -Surgipath, Richmond, IL, USA).
Localization of FAT10-DsRed fusion protein in cells
To determine the subcellular localization of the FAT10 protein, a FAT10-DsRed fusion construct was generated. The cytomegalovirus (CMV) promoter was introduced into pDsRed (Clontech, Palo Alto, CA, USA) to produce pCMVDsRed construct. The FAT10-DsRed fusion was generated via a two-step polymerase chain reaction (PCR) using primers as indicated in Figure 1a . In the first step, FAT10 and DsRed genes were amplified separately. FAT10 was amplified from human liver cDNA with primers C and D, while DsRed was amplified from pCMVDsRed plasmid using primers A and B ( Figure 1a ). The purified amplified FAT10 and DsRed PCR products were then mixed and another PCR reaction was performed using primers B and D to generate the fused FAT10-DsRed amplified product ( Figure 1a ). The fused FAT10-DsRed amplified product was then cloned into pCMVDsRed replacing the resident DsRed gene in the construct to generate pCMVFATDsRed. Identity of the fusion pCMVFATDsRed construct was confirmed by sequencing.
pCMVFATDsRed or its parental pCMVDsRed constructs were introduced into human embryonic liver cell line, WRL68 (European Collection of Cell Cultures, Salisbury, UK), plated on sterilized coverslips in six-well plates via calcium phosphate coprecipitation as described (Lee et al., 2000) . At 48 h after transfection, the cells were fixed in 2% paraformaldehyde and viewed under a fluorescence microscope.
Generation of recombinant FAT10 adenoviruses
Recombinant human FAT10 adenoviruses (AdFAT10) ( Figure  4c ) were generated as described (He et al., 1998) . The titer of the viruses was assessed by monitoring the number of fluorescence 293 cells after infection with serially diluted viral lysates and expressed as expression-forming units/ml.
Western blot analyses
Whole cell lysates 15-20 mg were separated on a 12% SDS-PAGE gel. The proteins on the gel were then transferred onto a PVDF membrane (BioRad, CA, USA) and hybridized with 0.1 mg/ml rabbit anti-FAT10 primary antibody and 1 : 10,000 HRP-conjugated goat anti-rabbit IgG (Pierce Biotechnology, IL, USA). The blot was then visualized using SuperSignal Duro Reagent (Pierce Biotechnology, IL, USA).
Localization of FAT10 protein in NIH3T3 cells
NIH3T3 cells (1 Â 10 4 ) were seeded onto coverslips in 24-well plates and grown in DMEM media containing 10% fetal bovine serum at 371C, 5% CO 2 for 2-3 days. AdControl or AdFAT10 adenoviruses were then added to the cells at a ratio of 20 : 1 (virus : cells) for 12 h. Fresh media were then added to replace the virus medium and the cells were incubated for another 36 h before being fixed in 2% paraformaldehyde. The fixed cells were permealized with 0.2% Triton X-100 for 10 min and stained with anti-FAT10 antibodies (2 mg/ml) for 1 h at 371C. After three washes in phosphate-buffered saline (PBS), the coverslip was incubated with Alexa Fluor s 647 chicken anti-rabbit IgG (H+L) (molecular probes, Eugene, OR, USA) for 1 h at room temperature. The cells were then washed thrice in PBS and mounted onto glass slides using FluorSave Reagent (Calbiochem, San Diego, CA, USA). The slides were observed with Zeiss LSM 510, laser scanning microscope (Heidelberg, Germany).
Expression studies in various cancers and tissues
The expression levels of FAT10 in various other cancers were determined with the use of the Cancer Profiling Array (Clontech, Palo Alto, CA, USA) containing paired normal/ tumor tissues covering 12 different cancers from 241 patients. In addition, FAT10 expression in various normal tissues and a number of transformed cell lines were determined using the Multiple Tissue Expression Array (Clontech, Palo Alto, CA, USA) spotted with 76 different tissue types. Each spotted tissue type was pooled from several individuals. Both arrays were hybridized with either the FAT10 cDNA probe or ubiquitin cDNA, the normalization probe provided by Clontech. These probes were generated as described earlier under conditions recommended by the manufacturer. Detailed information of these two blots may be found at http:// www.clontech.com. The probed blots were exposed to Biomax MS film or Fuji imaging plate. Samples with detectable signals in either the tumor or normal samples were used for densitometric analysis using Fluorchem TM v2.0 or the phosphorimager, BAS-2500. For the Cancer Profiling Array, FAT10 was considered differentially expressed between nontumor and tumor tissue if the intensity difference exceeded 1.5 times after normalization against signals obtained using the ubiquitin control probe.
Results
FAT10 is overexpressed in HCC tissue
Northern blot analysis was performed on 23 tumor and paired nontumorous samples from HCC patients to examine the levels of FAT10 gene expression in HCC (Figure 2) . A 1 kb band representing FAT10 mRNA was detected in 21 of the 23 HCC samples. In all, 19 of the 21 patients (90%) showed upregulation of FAT10 expression in tumor tissue (Figure 2 ).
FAT10 over-expression is localized to the nucleus of HCC cells
To examine the cell-type specificity of FAT10 expression in HCC liver tissue, in situ hybridization using antisense FAT10 riboprobes as well as immunohistochemistry utilizing anti-FAT10 antibodies that we generated were performed on cryosections of liver tissue from HCC patient #10 (see Figure 2) . As evident in Figure 3d , high levels of FAT10 transcript were detected primarily in HCC cells, with low and scattered signals in other cell types surrounding the HCC cells, including immune cells. Similarly, FAT10 protein expression was localized to the nuclei of HCC cells, and not other cell types around the HCC cells (Figure 4a ). In the paired adjacent nontumorous liver tissue from the same patient, FAT10 transcripts and protein were undetectable.
FAT10 protein is localized to the nucleus of cell lines in which the FAT10 gene is introduced Two additional experiments were carried out to further confirm the intracellular localization of FAT10 protein.
In the first experiment, a FAT10-DsRed fusion construct (pCMVFATDsRed) or its parental construct (pCMVDsRed) were introduced into human embryonic liver cell line, WRL68. Cells transfected with pCMVDsRed (negative control) exhibited uniform fluorescence in the nucleus and cytoplasm, whereas cells transfected with pCMVFATDsRed fusion construct showed intense red fluorescence only in the nucleus, indicating FAT10 protein localization to the nucleus (Figure 1b) . In the second experiment, control adenoviruses or recombinant adenoviruses expressing FAT10 were infected into NIH3T3 cells, and Western blot analyses and immunofluorescence analyses utilizing anti-FAT10 antibodies were performed. Figure 4b confirms the expression of FAT10 protein in NIH3T3 cells infected with AdFAT10 adenoviruses. As demonstrated in Figure 4c , the FAT10 protein was localized to the nucleus of cells infected with AdFAT10 adenoviruses.
FAT10 is also overexpressed in other cancers
To examine if FAT10 is also differentially expressed in cancers other than HCC, FAT10 cDNA was labeled and hybridized to an array blot containing representative paired tumor/normal tissues from several different cancers (Cancer Profiling Array, CPA TM , Clontech). The expression levels of FAT10 were consistently low in nontumorous tissues, but were upregulated in the majority of paired tumor samples (Figure 5a ). Notably, FAT10 was consistently upregulated in the tumors of the majority of patients with cancers of the gastrointestinal and female reproductive system (Figure 5b ). In addition, FAT10 was also upregulated in the single cervical cancer, single pancreatic cancer and two intestinal cancer samples represented on the array (Figure 5a ). The other cancers represented on the array (e.g. kidney, thyroid, etc.) did not show consistent up-or downregulation of FAT10 gene expression (Figure 5a,b) . FAT10 is overexpressed in gastrointestinal cancers CGL Lee et al In contrast to the FAT10 findings, expression of ubiquitin was uniform across all normal and tumor types represented on the array (Figure 5a ).
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Normal FAT10 expression is tissue specific
To study the tissue-specific distribution of FAT10 in normal tissue, FAT10 cDNA was labeled and hybridized to another array blot containing 76 different pooled normal tissue types (Multiple Tissue Array, MTE TM , Clontech). FAT10 expression was detected in a number of different tissues including the gastrointestinal system, kidney, lung and prostate gland (Figure 6a ). In contrast, tissues from the brain and adrenal gland did not show any detectable signals. Highest expression of FAT10 was observed in tissues of the reticuloendothelial system (e.g. thymus, spleen) and the gastrointestinal system.
We further compared FAT10 expression levels in fetal and adult tissues (Figure 6b ). There was no difference between fetal and adult tissues of the reticuloendothelial system, and no detectable expression in both fetal and adult brain and heart. Interestingly, higher expression was observed in fetal compared to adult liver, while adult kidney showed higher expression compared with fetal kidney.
These results suggest that normal FAT10 expression is both developmentally and tissue-specifically regulated.
Discussion
Upregulation of FAT10 gene expression in HCC FAT10 belongs to a growing group of ubiquitin-related proteins involved in a variety of fundamental cellular processes including signal transduction, protein translocation and cell-cycle regulation (for a review see, Jentsch and Pyrowolakis, 2000) . A well-characterized member of this family, SUMO1, has been shown to modify a number of oncoproteins like p53 and c-jun, thus altering their activity (Sampson et al., 2001) . Also, the BRCA1 gene, a breast cancer susceptibility gene, has been shown to encode an E3 ubiquitin ligase (Ruffner et al., 2001) . FAT10 has been reported to bind noncovalently to MAD2 (Liu et al., 1999) , a protein necessary for maintaining spindle integrity during mitosis (Shah and Cleveland, 2000) , suggesting that it may play a role in regulating genomic stability. Indeed, MAD2 dysregulation has been associated with chromosomal instability (Wang et al., 2000; Gemma et al., 2001 ) and has been shown to cause increased tumor incidence in mice (Michel et al., 2001) .
Earlier reports have suggested that FAT10 protein is localized to the cytoplasm of g-interferon-induced B Figure 5 FAT10 expression in paired samples of 12 different types of cancers from 241 patients: 50 breast cancers, 42 uterine cancers, 53 colorectal cancers, 27 stomach cancers, 14 ovarian cancers, 21 lung cancers, 20 kidney cancers, six thyroid cancers, four prostate cancers, one pancreatic cancer, two small intestinal cancer and one cervical cancer. (a) Commercially available blot (Cancer Profiling Array, Clontech, CA, USA) containing SMARTt-amplified cDNA derived from RNA of tissues from different cancer patients was probed with either 32 P-labeled FAT10 (left panel), or 32 P-labeled ubiquitin (right panel) as a normalization control. The intensity of the FAT10 probe signal was quantitated using Fuji BAS2500 and normalized against ubiquitin, a housekeeping gene. FAT10 signals were not detectable in either the tumor or paired nontumorous tissue of one breast cancer, eight uterine cancers, one stomach cancer, two ovarian cancers, one lung cancer, one rectal cancer and two thyroid cancers. (b) Graphical representation of the differential expression of FAT10 in seven different cancers. The dark shaded bar denotes the percentage (%) of patients in which the FAT10 gene is overexpressed by at least 1.5 times in tumor tissue, the lightly shaded bar denotes the percentage (%) of patients in which FAT10 is underexpress by at least 1.5 times in tumor tissue, while the unshaded bar represents the percentage (%) of patients in which the FAT10 gene expression remains unchanged (differential expression less than 1.5 times) or undetectable lymphoblastoid (JY) cells based on Western blot analyses of fractionated cells (Liu et al., 1999) , and to the cytoplasm of murine fibroblast cells via immunofluorescence of the HA in HA-tagged FAT10 protein (Raasi et al., 2001) . However, their results were not conclusive as it is not possible to rule out HA directed localization from the data of Raasi et al. (2001) , since localization of HA-only negative (vector) control was not shown. Similarly, in the FAT10 protein localization study of Liu et al. (1999) , no proper subcellular markers were used as controls in their Western blots. In this study, utilizing three different approaches, we demonstrated that FAT10 protein is in fact localized to the nuclei of HCC cells (Figures 1 and 4a and 4c ). The nuclear localization of FAT10 in HCC cells and its reported binding to MAD2 protein is suggestive of a role of FAT10 in the regulation of cell division. In interphase cells, MAD2 is predominantly localized to the cytoplasm, unless MAD1 is overexpressed and translocates MAD2 to the nucleus (Iwanaga et al., 2002) . Curiously, we found that FAT10 protein was localized to the nucleus in interphase cells, and hence are in a different compartment from MAD2. It is possible that overexpression of FAT10 induces the overexpression of MAD1 facilitating the translocation of MAD2 into the nucleus. However, we did not observe increased MAD1 protein expression in two different cell lines infected with AdFAT10 adenoviruses (data not shown). Another possible hypothesis is that during interphase, FAT10 and MAD2 remain in different cellular compartments and do not interact. When cells go into mitosis and the nuclear membrane dissolves, FAT10 and MAD2 are brought into close proximity facilitating their interaction. Increased expression of FAT10 in the nuclei of cancer cells may result in increased and possibly abnormal interaction of FAT10 with MAD2 during mitosis, thus preventing MAD2 from functioning appropriately as a 'wait anaphase' signal at the spindle assembly checkpoint. Studies are in progress to further examine the interaction between FAT10 and MAD2 during mitosis and to elucidate the molecular role of FAT10 in carcinogenesis.
FAT10 was also reported to induce apoptosis in HeLa and mouse fibroblast cell lines (Raasi et al., 2001) . However, we have thus far found no evidence of increased cell death or apoptosis in several cells lines (NIH3T3, Hep3B and Hct116, etc.) in which the FAT10 gene was introduced. The survival and doubling times of these cells are similar to their parental non-FAT10 overexpressing lines (data not shown).
Given a possible role of FAT10 in fundamental cellular processes leading to tumorigenesis, we investigated FAT10 expression in HCC using Northern blot analyses. We found that, overall, B90% of HCC tumors showed upregulation of the FAT10 gene expression (Figure 2) . We also examined FAT10 expression in other cancers using a cancer profiling array spotted with cDNAs from 241 paired cancer/normal samples. Several different types of cancers were found to exhibit upregulation of FAT10 expression in the tumor tissues compared to their paired nontumorous samples (Figure 5a, b) . Of note, FAT10 expression was upregulated in a higher proportion of cancers of the gastrointestinal tract (stomach, intestinal and colorectal) and the female reproductive system (uterine, cervical and ovarian). In other cancer types such as thyroid, prostate and kidney, we did not detect any consistent up-or downregulation.
Developmental and tissue-specific expression of FAT10
We further analysed the normal tissue distribution of FAT10 expression using a multiple tissue array containing 76 different normal tissues. We found that FAT10 is expressed at high levels in tissues of the gastrointestinal and reticuloendothelial systems, at low levels in the cardiovascular and reproductive tissues, but is strikingly absent in the brain (Figure 6 ). FAT10 appears to be expressed mostly in tissues associated with the immunological system, such as the reticuloendothelial and mucosal-associated lymphoid tissues (MALT) systems (e.g. spleen, thymus and lungs). This is consistent with previous reports that FAT10 expression is inducible by Epstein-Barr virus infection, growth factors such as interferon-g and TNF-a (Raasi et al., 1999) and is linked to the maturation state of B cells and the antigen presentation of dendritic cells (Bates et al., 1997) . In contrast, FAT10 is conspicuously absent in both fetal and adult brain, an immunologically privileged organ. It is thus possible that the overexpression of FAT10 in the specific cancers is because of a general immunological response during carcinogenesis.
This possibility is unlikely based on our microarray analyses of tumor versus paired nontumorous liver samples from four HCC patients. Although all four of the HCC samples showed significant overexpression of the FAT10 gene in the tumor tissues compared to their paired nontumorous tissues, we did not find corroborating evidence of an immunological response through the upregulation of immune response genes like b-2 microglobulin as well as TNF-stimulated genes like c-jun and c-fos (data not shown). Also, none of the 22 key genes in the inflammatory response represented on the microarray (i.e. the arachidonates, prostaglandins and phospholipase A2) were significantly upregulated except for phospholipase A2 group IIA, a gene linked to arthritic inflammation, which saw marginal upregulation in only one of the four HCC patients (data not (Figures 3 and 4a ). These lines of evidence strongly suggest that FAT10 overexpression is unlikely to be the result of a general immunological or inflammatory response in cancer. Since FAT10 is homologous to ubiquitin, a molecule responsible for protein degradation, FAT10 may also be involved in protein metabolism. As such, FAT10 overexpression may be merely the consequence of the general overexpression of genes involved in increased protein synthesis and degradation during carcinogenesis. Based on our microarray analyses of tumor versus paired nontumorous liver samples from four HCC patients, however, this possibility is also unlikely. Although FAT10 is significantly overexpressed in all four HCC tumors examined, there is no consistent evidence of a general overexpression of proteins involved in protein synthesis or degradation. Notably, ubiquitin, which plays an important role in protein degradation, is not significantly differentially expressed in the tumors of any of the four HCC patients or the tumors of different cancers from 241 patients (Figure 5a) . None of the approximately 200 candidate genes classified to play (or potentially play) a role in protein cleavage and degradation were found to be significantly differentially expressed in all four HCC patients: only four of these genes (transmembrane serine protease 2, plasma kallikrein B (Fletcher factor) 1, plasminogen, inter-a (globulin) inhibitor H4) were found to be significantly underexpressed in three of four HCC tumors, while two (cathepsin C, proteasome subunit, b 4) were found to be significantly overexpressed in two of the four HCC tumors. Furthermore, none of the more than 400 genes implicated to be involved in translation initiation, elongation or post-translational modification processes were consistently significantly differentially expressed in all four HCC patients; only 20 genes, primarily ribosomal proteins are overexpressed in two of the four patients. Hence, these data strongly suggest that FAT10 overexpression is unlikely to be the result of a general increase in protein metabolism or an immunological/ inflammatory response in cancer. Given FAT10's localization to nuclei of HCC cells, but not surrounding non-HCC cells (Figures 1 and 4) , it is possible that FAT10 may play a role in cancer development through the dysregulation of MAD2 (Liu et al., 1999) .
In conclusion, we have demonstrated that FAT10 gene expression is highly upregulated in HCC and other gastrointestinal and gynecological cancers. This study represents the first documentation of an association between FAT10 overexpression and these cancers.
